64. 血栓性血小板減少性紫斑病 Disease details / Clinical trials / Drug dev / DR info
臨床試験数 : 92 / 薬物数 : 85 - (DrugBank : 21) / 標的遺伝子数 : 18 - 標的パスウェイ数 : 76
薬物ごとの開発者（Primary Sponsor）、臨床試験情報（抜粋）です。
ALX-0081
ABLYNX N.V.
2010 - EUCTR2010-019375-30-IT Austria;Belgium;Germany;Italy;Spain;United Kingdom;
ABLYNX NV
- Phase 3 EUCTR2015-001098-42-IT Australia;Austria;Belgium;Canada;Czech Republic;Czechia;France;Germany;Hungary;Israel;Italy;Netherlands;New Zealand;Spain;Switzerland;Turkey;United Kingdom;United States;
Ablynx
2011 - EUCTR2010-019375-30-ES Austria;Belgium;Germany;Italy;Spain;United Kingdom;
2010 Phase 2 EUCTR2010-019375-30-GB Austria;Belgium;Canada;Germany;Israel;Italy;Russian Federation;Spain;Switzerland;United Kingdom;United States;
2010 Phase 2 EUCTR2010-019375-30-BE Australia;Austria;Belgium;Germany;Israel;Italy;Spain;Switzerland;United Kingdom;United States;
2010 - EUCTR2010-019375-30-DE Austria;Belgium;Canada;Germany;Israel;Italy;Russian Federation;Spain;Switzerland;United Kingdom;United States;
2010 - EUCTR2010-019375-30-AT Austria;Belgium;Canada;Germany;Israel;Italy;Russian Federation;Spain;Switzerland;United Kingdom;United States;
Ablynx NV
2016 Phase 3 EUCTR2015-001098-42-NL Australia;Austria;Belgium;Canada;Czech Republic;France;Germany;Hungary;Israel;Italy;Netherlands;New Zealand;Spain;Switzerland;Turkey;United Kingdom;United States;
2015 Phase 3 EUCTR2015-001098-42-HU Australia;Austria;Belgium;Canada;Czech Republic;France;Germany;Hungary;Israel;Italy;Netherlands;Spain;Switzerland;Turkey;United Kingdom;United States;
2015 Phase 3 EUCTR2015-001098-42-ES Australia;Austria;Belgium;Canada;Czech Republic;France;Germany;Hungary;Israel;Italy;Netherlands;New Zealand;Spain;Switzerland;Turkey;United Kingdom;United States;
2015 Phase 3 EUCTR2015-001098-42-DE Australia;Austria;Belgium;Canada;Czech Republic;France;Germany;Hungary;Israel;Italy;Netherlands;New Zealand;Spain;Switzerland;Turkey;United Kingdom;United States;
2015 Phase 3 EUCTR2015-001098-42-CZ Australia;Austria;Belgium;Canada;Czech Republic;France;Germany;Hungary;Israel;Italy;Netherlands;Spain;Switzerland;Turkey;United Kingdom;United States;
2015 Phase 3 EUCTR2015-001098-42-BE Australia;Austria;Belgium;Canada;Czech Republic;France;Germany;Hungary;Israel;Italy;Netherlands;New Zealand;Spain;Switzerland;Turkey;United Kingdom;United States;
2015 Phase 3 EUCTR2015-001098-42-AT Australia;Austria;Belgium;Canada;Czech Republic;France;Germany;Hungary;Israel;Italy;Netherlands;Spain;Switzerland;Turkey;United Kingdom;United States;
- Phase 3 EUCTR2015-001098-42-Outside-EU/EEA Australia;Canada;Israel;Switzerland;Turkey;United States;
ARC 1779
Archemix Corp.
2007 - EUCTR2007-004371-19-AT Austria;
ARC1779 Injection
Archemix Corp.
2008 Phase 2 NCT00726544 Austria;Canada;Italy;United Kingdom;United States;
2007 - EUCTR2007-004371-19-AT Austria;
Anfibatide
Lee's Pharmaceutical Limited
2019 Phase 2 NCT04021173 China;
Anti-von Willebrand Factor Nanobody
ABLYNX N.V.
2010 - EUCTR2010-019375-30-IT Austria;Belgium;Germany;Italy;Spain;United Kingdom;
Ablynx
2011 - EUCTR2010-019375-30-ES Austria;Belgium;Germany;Italy;Spain;United Kingdom;
Anti-von Willebrand Factor Nanobody, Caplacizumab
Ablynx
2010 - EUCTR2010-019375-30-DE Austria;Belgium;Canada;Germany;Israel;Italy;Russian Federation;Spain;Switzerland;United Kingdom;United States;
2010 - EUCTR2010-019375-30-AT Austria;Belgium;Canada;Germany;Israel;Italy;Russian Federation;Spain;Switzerland;United Kingdom;United States;
Anti-von Willebrand Factor Nanobody, INN = Caplacizumab
Ablynx
2010 Phase 2 EUCTR2010-019375-30-GB Austria;Belgium;Canada;Germany;Israel;Italy;Russian Federation;Spain;Switzerland;United Kingdom;United States;
2010 Phase 2 EUCTR2010-019375-30-BE Australia;Austria;Belgium;Germany;Israel;Italy;Spain;Switzerland;United Kingdom;United States;
Apadamtase alfa
BAXALTA INNOVATIONS GMBH
2022 Phase 3 EUCTR2020-003348-10-IT Australia;Austria;Belgium;Brazil;Canada;China;Colombia;Czechia;Denmark;France;Germany;Hungary;India;Israel;Italy;Japan;Korea, Republic of;Netherlands;Norway;Poland;Portugal;Russian Federation;Serbia;Spain;Sweden;Switzerland;Taiwan;Thailand;Turkey;Ukraine;United Kingdom;United States;
2020 Phase 2 EUCTR2018-003775-35-IT Canada;France;Germany;Italy;Netherlands;Spain;Switzerland;United Kingdom;United States;
2019 Phase 3 EUCTR2017-000858-18-IT Austria;Canada;France;Germany;Italy;Japan;Poland;Spain;Switzerland;United Kingdom;United States;
Baxalta Innovation GmbH
2019 Phase 2 EUCTR2018-003775-35-DE Canada;France;Germany;Italy;Netherlands;Spain;Switzerland;United Kingdom;United States;
Baxalta Innovations GmbH
2020 Phase 3 EUCTR2020-003348-10-GB Australia;Austria;Belgium;Brazil;Canada;China;Colombia;Czechia;Denmark;France;Germany;Hungary;India;Israel;Italy;Japan;Korea, Republic of;Netherlands;Norway;Poland;Portugal;Russian Federation;Serbia;Spain;Sweden;Switzerland;Taiwan;Thailand;Turkey;Ukraine;United Kingdom;United States;
2019 Phase 3 EUCTR2017-000858-18-DE Austria;Canada;France;Germany;Italy;Japan;Poland;Spain;Switzerland;United Kingdom;United States;
2019 Phase 2 EUCTR2018-003775-35-GB Canada;France;Germany;Italy;Spain;United Kingdom;United States;
2019 Phase 2 EUCTR2018-003775-35-ES Canada;France;Germany;Italy;Netherlands;Spain;Switzerland;United Kingdom;United States;
2018 Phase 3 EUCTR2017-000858-18-AT Austria;Canada;France;Germany;Italy;Japan;Poland;Spain;Switzerland;United Kingdom;United States;
2017 Phase 3 EUCTR2017-000858-18-GB Austria;Canada;France;Germany;Italy;Japan;Poland;Spain;Switzerland;United Kingdom;United States;
2017 Phase 3 EUCTR2017-000858-18-ES Austria;Canada;France;Germany;Italy;Japan;Poland;Spain;Switzerland;United Kingdom;United States;
- Phase 3 EUCTR2020-003348-10-PL Australia;Austria;Belgium;Brazil;Canada;China;Colombia;Czechia;Denmark;France;Germany;Hungary;India;Israel;Italy;Japan;Korea, Republic of;Netherlands;Norway;Poland;Portugal;Russian Federation;Serbia;Spain;Sweden;Switzerland;Taiwan;Thailand;Turkey;Ukraine;United Kingdom;United States;
- Phase 3 EUCTR2020-003348-10-FR Australia;Austria;Belgium;Brazil;Canada;China;Colombia;Czechia;Denmark;France;Germany;Hungary;India;Israel;Italy;Japan;Korea, Republic of;Netherlands;Norway;Poland;Portugal;Russian Federation;Serbia;Spain;Sweden;Switzerland;Taiwan;Thailand;Turkey;Ukraine;United Kingdom;United States;
- Phase 3 EUCTR2020-003348-10-AT Australia;Austria;Belgium;Brazil;Canada;China;Colombia;Czechia;Denmark;France;Germany;Hungary;India;Israel;Italy;Japan;Korea, Republic of;Netherlands;Norway;Poland;Portugal;Russian Federation;Serbia;Spain;Sweden;Switzerland;Taiwan;Thailand;Turkey;Ukraine;United Kingdom;United States;
- Phase 3 EUCTR2017-000858-18-PL Austria;Canada;France;Germany;Italy;Japan;Poland;Spain;Switzerland;United Kingdom;United States;
- Phase 3 EUCTR2017-000858-18-FR Austria;Canada;France;Germany;Italy;Japan;Poland;Spain;Switzerland;United Kingdom;United States;
Apademtase alfa
Baxalta Innovations GmbH
2018 Phase 3 EUCTR2017-000858-18-AT Austria;Canada;France;Germany;Italy;Japan;Poland;Spain;Switzerland;United Kingdom;United States;
BAX930
Baxalta Innovations GmbH
2015 Phase 1 EUCTR2012-003221-19-DE Austria;Germany;Japan;Poland;Switzerland;United Kingdom;United States;
2015 - EUCTR2012-003221-19-PL Austria;Germany;Japan;Poland;Switzerland;United Kingdom;United States;
2013 Phase 1 EUCTR2012-003221-19-GB Austria;Germany;Japan;Poland;United Kingdom;United States;
2012 - EUCTR2012-003221-19-AT Austria;Germany;Japan;Poland;United Kingdom;United States;
Baxalta now part of Shire
2017 Phase 3 NCT03393975 Austria;France;Germany;Italy;Japan;Poland;Spain;Switzerland;United Kingdom;United States;
BAX930 - RECOMBINANT HUMAN ADAMTS13
BAXALTA INNOVATIONS GMBH
2020 Phase 2 EUCTR2018-003775-35-IT Canada;France;Germany;Italy;Netherlands;Spain;Switzerland;United Kingdom;United States;
Baxalta Innovation GmbH
2019 Phase 2 EUCTR2018-003775-35-DE Canada;France;Germany;Italy;Netherlands;Spain;Switzerland;United Kingdom;United States;
Baxalta Innovations GmbH
2019 Phase 2 EUCTR2018-003775-35-GB Canada;France;Germany;Italy;Spain;United Kingdom;United States;
2019 Phase 2 EUCTR2018-003775-35-ES Canada;France;Germany;Italy;Netherlands;Spain;Switzerland;United Kingdom;United States;
BAX930 or SHP655
BAXALTA INNOVATIONS GMBH
2019 Phase 3 EUCTR2017-000858-18-IT Austria;Canada;France;Germany;Italy;Japan;Poland;Spain;Switzerland;United Kingdom;United States;
Baxalta Innovations GmbH
2019 Phase 3 EUCTR2017-000858-18-DE Austria;Canada;France;Germany;Italy;Japan;Poland;Spain;Switzerland;United Kingdom;United States;
2018 Phase 3 EUCTR2017-000858-18-AT Austria;Canada;France;Germany;Italy;Japan;Poland;Spain;Switzerland;United Kingdom;United States;
2017 Phase 3 EUCTR2017-000858-18-GB Austria;Canada;France;Germany;Italy;Japan;Poland;Spain;Switzerland;United Kingdom;United States;
2017 Phase 3 EUCTR2017-000858-18-ES Austria;Canada;France;Germany;Italy;Japan;Poland;Spain;Switzerland;United Kingdom;United States;
- Phase 3 EUCTR2017-000858-18-PL Austria;Canada;France;Germany;Italy;Japan;Poland;Spain;Switzerland;United Kingdom;United States;
- Phase 3 EUCTR2017-000858-18-FR Austria;Canada;France;Germany;Italy;Japan;Poland;Spain;Switzerland;United Kingdom;United States;
Bortezomib Injection
Peking Union Medical College Hospital
2021 Phase 4 NCT05135442 China;
Cablivi®
University of Cologne
2021 - NCT04985318 Germany;
Caplacizumab
Ablynx
2015 Phase 3 NCT02553317 Australia;Austria;Belgium;Canada;Czech Republic;Czechia;France;Germany;Hungary;Israel;Italy;Netherlands;Spain;Switzerland;Turkey;United Kingdom;United States;
2011 Phase 2 NCT01151423 Australia;Austria;Belgium;Bulgaria;France;Germany;Israel;Italy;Romania;Spain;Switzerland;United Kingdom;United States;
Ablynx NV
2016 Phase 3 EUCTR2015-001098-42-NL Australia;Austria;Belgium;Canada;Czech Republic;France;Germany;Hungary;Israel;Italy;Netherlands;New Zealand;Spain;Switzerland;Turkey;United Kingdom;United States;
2015 Phase 3 EUCTR2015-001098-42-CZ Australia;Austria;Belgium;Canada;Czech Republic;France;Germany;Hungary;Israel;Italy;Netherlands;Spain;Switzerland;Turkey;United Kingdom;United States;
- Phase 3 EUCTR2015-001098-42-Outside-EU/EEA Australia;Canada;Israel;Switzerland;Turkey;United States;
Sanofi
2022 - NCT05263193 France;
2016 Phase 3 NCT02878603 Austria;Belgium;Canada;Czech Republic;Czechia;France;Hungary;Israel;Italy;Spain;Switzerland;Turkey;United Kingdom;United States;
University Hospital, Rouen
2021 Phase 2 NCT04720261 -
Caplacizumab (ALX-0081)
Sanofi
2019 Phase 2/Phase 3 NCT04074187 Japan;
Caplacizumab (an anti-von Willebrand Factor Nanobody ALX-0081)
ABLYNX NV
- Phase 3 EUCTR2016-001503-23-IT Austria;Belgium;Canada;Czech Republic;Czechia;France;Germany;Hungary;Israel;Italy;Netherlands;Spain;Switzerland;Turkey;United Kingdom;United States;
Ablynx NV
2017 Phase 3 EUCTR2016-001503-23-NL Australia;Austria;Belgium;Canada;Czech Republic;France;Germany;Hungary;Israel;Italy;Netherlands;Spain;Switzerland;Turkey;United Kingdom;United States;
2017 Phase 3 EUCTR2016-001503-23-FR Australia;Austria;Belgium;Canada;Czech Republic;France;Germany;Hungary;Israel;Italy;Netherlands;Spain;Switzerland;Turkey;United Kingdom;United States;
2017 Phase 3 EUCTR2016-001503-23-DE Australia;Austria;Belgium;Canada;Czech Republic;France;Germany;Hungary;Israel;Italy;Netherlands;Spain;Switzerland;Turkey;United Kingdom;United States;
2016 Phase 3 EUCTR2016-001503-23-HU Australia;Austria;Belgium;Canada;Czech Republic;France;Germany;Hungary;Israel;Italy;Netherlands;Spain;Switzerland;Turkey;United Kingdom;United States;
2016 Phase 3 EUCTR2016-001503-23-GB Austria;Belgium;Canada;Czech Republic;France;Germany;Hungary;Israel;Italy;Netherlands;Spain;Switzerland;Turkey;United Kingdom;United States;
2016 Phase 3 EUCTR2016-001503-23-ES Australia;Austria;Belgium;Canada;Czech Republic;France;Germany;Hungary;Israel;Italy;Netherlands;Spain;Switzerland;Turkey;United Kingdom;United States;
2016 Phase 3 EUCTR2016-001503-23-CZ Austria;Belgium;Canada;Czech Republic;France;Germany;Hungary;Israel;Italy;Netherlands;Spain;Switzerland;Turkey;United Kingdom;United States;
2016 Phase 3 EUCTR2016-001503-23-BE Austria;Belgium;Canada;Czech Republic;France;Germany;Hungary;Israel;Italy;Netherlands;Spain;Switzerland;Turkey;United Kingdom;United States;
2016 Phase 3 EUCTR2016-001503-23-AT Austria;Belgium;Canada;Czech Republic;France;Germany;Hungary;Israel;Italy;Netherlands;Spain;Switzerland;Turkey;United Kingdom;United States;
Caplacizumab (an anti-von Willebrand Factor Nanobody)
ABLYNX NV
- Phase 3 EUCTR2015-001098-42-IT Australia;Austria;Belgium;Canada;Czech Republic;Czechia;France;Germany;Hungary;Israel;Italy;Netherlands;New Zealand;Spain;Switzerland;Turkey;United Kingdom;United States;
Ablynx NV
2015 Phase 3 EUCTR2015-001098-42-HU Australia;Austria;Belgium;Canada;Czech Republic;France;Germany;Hungary;Israel;Italy;Netherlands;Spain;Switzerland;Turkey;United Kingdom;United States;
2015 Phase 3 EUCTR2015-001098-42-ES Australia;Austria;Belgium;Canada;Czech Republic;France;Germany;Hungary;Israel;Italy;Netherlands;New Zealand;Spain;Switzerland;Turkey;United Kingdom;United States;
2015 Phase 3 EUCTR2015-001098-42-DE Australia;Austria;Belgium;Canada;Czech Republic;France;Germany;Hungary;Israel;Italy;Netherlands;New Zealand;Spain;Switzerland;Turkey;United Kingdom;United States;
2015 Phase 3 EUCTR2015-001098-42-BE Australia;Austria;Belgium;Canada;Czech Republic;France;Germany;Hungary;Israel;Italy;Netherlands;New Zealand;Spain;Switzerland;Turkey;United Kingdom;United States;
2015 Phase 3 EUCTR2015-001098-42-AT Australia;Austria;Belgium;Canada;Czech Republic;France;Germany;Hungary;Israel;Italy;Netherlands;Spain;Switzerland;Turkey;United Kingdom;United States;
Corticosteroid treatment (Methylprednisolone or prednisolone)
Sanofi
2019 Phase 2/Phase 3 NCT04074187 Japan;
Corticosteroids
New England Research Institutes
2009 Phase 3 NCT00799773 United States;
Cryosupernatant plasma
Octapharma
2007 Phase 3 NCT00411801 United States;
Cyclosporine
Ohio State University
2007 Phase 3 NCT00713193 United States;
Danazol
Icahn School of Medicine at Mount Sinai
2008 Phase 2 NCT00953771 United States;
Desmopressin acetate
Archemix Corp.
2007 - EUCTR2007-004371-19-AT Austria;
Dexamethasone
David Gomez Almaguer
2020 Phase 2 NCT04588194 Mexico;
HMED-IdeS
Hansa Medical AB
2016 Phase 2 EUCTR2016-000249-30-GB United Kingdom;
IDEC-C2B8, Ro 45-2294
University College London
2005 Phase 2 EUCTR2005-002274-30-GB United Kingdom;
IdeS (0.25 mg/kg)
Hansa Biopharma AB
2016 Phase 2 NCT02854059 United Kingdom;
IdeS (0.50 mg/kg)
Hansa Biopharma AB
2016 Phase 2 NCT02854059 United Kingdom;
Immunosuppressive treatment (eg, rituximab)
Sanofi
2019 Phase 2/Phase 3 NCT04074187 Japan;
MabThera
University College London
2005 Phase 2 EUCTR2005-002274-30-GB United Kingdom;
Minirin
Archemix Corp.
2007 - EUCTR2007-004371-19-AT Austria;
OMS721 100 mg/ml Injection solution, OMS00620646, OMS620646, MASP-2 Antibody
Omeros Corporation
2014 Phase 2 EUCTR2014-001032-11-PL Belgium;Bulgaria;Hong Kong;Italy;Lithuania;Malaysia;New Zealand;Poland;Singapore;Taiwan;Thailand;United States;
2014 Phase 2 EUCTR2014-001032-11-LT Belgium;Bulgaria;Hong Kong;Italy;Lithuania;Malaysia;New Zealand;Poland;Singapore;Taiwan;Thailand;United States;
2014 Phase 2 EUCTR2014-001032-11-BE Belarus;Belgium;Bulgaria;Germany;Hong Kong;Italy;Lithuania;Malaysia;New Zealand;Poland;Switzerland;Taiwan;Thailand;Turkey;United Kingdom;United States;
OMS721 185 mg/ml Injection solution, OMS00620646, OMS620646, MASP-2 Antibody
Omeros Corporation
2014 Phase 2 EUCTR2014-001032-11-PL Belgium;Bulgaria;Hong Kong;Italy;Lithuania;Malaysia;New Zealand;Poland;Singapore;Taiwan;Thailand;United States;
2014 Phase 2 EUCTR2014-001032-11-LT Belgium;Bulgaria;Hong Kong;Italy;Lithuania;Malaysia;New Zealand;Poland;Singapore;Taiwan;Thailand;United States;
Octaplas
Octapharma
2017 - NCT01938404 United States;
Octaplas SD
Baxalta Innovations GmbH
2018 Phase 3 EUCTR2017-000858-18-AT Austria;Canada;France;Germany;Italy;Japan;Poland;Spain;Switzerland;United Kingdom;United States;
Octaplas infusion
St. Olavs Hospital
2012 Phase 4 NCT01754545 Norway;
OctaplasLG®
Octapharma
2018 - NCT03369314 France;New Caledonia;
Octaplas®LG
Baxalta Innovations GmbH
2018 Phase 3 EUCTR2017-000858-18-AT Austria;Canada;France;Germany;Italy;Japan;Poland;Spain;Switzerland;United Kingdom;United States;
Octostim
Archemix Corp.
2007 - EUCTR2007-004371-19-AT Austria;
Plasma exchange
New England Research Institutes
2009 Phase 3 NCT00799773 United States;
Plasma exchange (PE)
Sanofi
2019 Phase 2/Phase 3 NCT04074187 Japan;
Pooled Plasma (Human), Solvent/Detergent Treated
Baxalta Innovations GmbH
2018 Phase 3 EUCTR2017-000858-18-AT Austria;Canada;France;Germany;Italy;Japan;Poland;Spain;Switzerland;United Kingdom;United States;
Prednisone
Ohio State University
2007 Phase 3 NCT00713193 United States;
RADAMTS-13
Baxalta now part of Shire(ICCC: IQVIA Services Japan K.K.)
2019 Phase 3 JPRN-JapicCTI-194991 Japan, North America, Europe;
Recombinant A Disintegrin And Metalloproteinase with Thrombospondin Type-1 Motifs 13 (rADAMTS13)
BAXALTA INNOVATIONS GMBH
2020 Phase 2 EUCTR2018-003775-35-IT Canada;France;Germany;Italy;Netherlands;Spain;Switzerland;United Kingdom;United States;
Baxalta Innovation GmbH
2019 Phase 2 EUCTR2018-003775-35-DE Canada;France;Germany;Italy;Netherlands;Spain;Switzerland;United Kingdom;United States;
Baxalta Innovations GmbH
2019 Phase 2 EUCTR2018-003775-35-GB Canada;France;Germany;Italy;Spain;United Kingdom;United States;
2019 Phase 2 EUCTR2018-003775-35-ES Canada;France;Germany;Italy;Netherlands;Spain;Switzerland;United Kingdom;United States;
Recombinant A Disintegrin and Metalloproteinase Thrombospondin Type-1 Motifs 13
BAXALTA INNOVATIONS GMBH
2022 Phase 3 EUCTR2020-003348-10-IT Australia;Austria;Belgium;Brazil;Canada;China;Colombia;Czechia;Denmark;France;Germany;Hungary;India;Israel;Italy;Japan;Korea, Republic of;Netherlands;Norway;Poland;Portugal;Russian Federation;Serbia;Spain;Sweden;Switzerland;Taiwan;Thailand;Turkey;Ukraine;United Kingdom;United States;
Baxalta Innovations GmbH
2020 Phase 3 EUCTR2020-003348-10-GB Australia;Austria;Belgium;Brazil;Canada;China;Colombia;Czechia;Denmark;France;Germany;Hungary;India;Israel;Italy;Japan;Korea, Republic of;Netherlands;Norway;Poland;Portugal;Russian Federation;Serbia;Spain;Sweden;Switzerland;Taiwan;Thailand;Turkey;Ukraine;United Kingdom;United States;
- Phase 3 EUCTR2020-003348-10-PL Australia;Austria;Belgium;Brazil;Canada;China;Colombia;Czechia;Denmark;France;Germany;Hungary;India;Israel;Italy;Japan;Korea, Republic of;Netherlands;Norway;Poland;Portugal;Russian Federation;Serbia;Spain;Sweden;Switzerland;Taiwan;Thailand;Turkey;Ukraine;United Kingdom;United States;
- Phase 3 EUCTR2020-003348-10-FR Australia;Austria;Belgium;Brazil;Canada;China;Colombia;Czechia;Denmark;France;Germany;Hungary;India;Israel;Italy;Japan;Korea, Republic of;Netherlands;Norway;Poland;Portugal;Russian Federation;Serbia;Spain;Sweden;Switzerland;Taiwan;Thailand;Turkey;Ukraine;United Kingdom;United States;
- Phase 3 EUCTR2020-003348-10-AT Australia;Austria;Belgium;Brazil;Canada;China;Colombia;Czechia;Denmark;France;Germany;Hungary;India;Israel;Italy;Japan;Korea, Republic of;Netherlands;Norway;Poland;Portugal;Russian Federation;Serbia;Spain;Sweden;Switzerland;Taiwan;Thailand;Turkey;Ukraine;United Kingdom;United States;
Recombinant A Disintegrin and Metalloproteinase with Thrombospondin Type-1 Motifs
Baxalta Innovations GmbH
2020 Phase 3 EUCTR2020-003348-10-GB Australia;Austria;Belgium;Brazil;Canada;China;Colombia;Czechia;Denmark;France;Germany;Hungary;India;Israel;Italy;Japan;Korea, Republic of;Netherlands;Norway;Poland;Portugal;Russian Federation;Serbia;Spain;Sweden;Switzerland;Taiwan;Thailand;Turkey;Ukraine;United Kingdom;United States;
- Phase 3 EUCTR2020-003348-10-PL Australia;Austria;Belgium;Brazil;Canada;China;Colombia;Czechia;Denmark;France;Germany;Hungary;India;Israel;Italy;Japan;Korea, Republic of;Netherlands;Norway;Poland;Portugal;Russian Federation;Serbia;Spain;Sweden;Switzerland;Taiwan;Thailand;Turkey;Ukraine;United Kingdom;United States;
- Phase 3 EUCTR2020-003348-10-FR Australia;Austria;Belgium;Brazil;Canada;China;Colombia;Czechia;Denmark;France;Germany;Hungary;India;Israel;Italy;Japan;Korea, Republic of;Netherlands;Norway;Poland;Portugal;Russian Federation;Serbia;Spain;Sweden;Switzerland;Taiwan;Thailand;Turkey;Ukraine;United Kingdom;United States;
- Phase 3 EUCTR2020-003348-10-AT Australia;Austria;Belgium;Brazil;Canada;China;Colombia;Czechia;Denmark;France;Germany;Hungary;India;Israel;Italy;Japan;Korea, Republic of;Netherlands;Norway;Poland;Portugal;Russian Federation;Serbia;Spain;Sweden;Switzerland;Taiwan;Thailand;Turkey;Ukraine;United Kingdom;United States;
Recombinant A Disintegrin and Metalloproteinase with Thrombospondin Type-1 Motifs 13
BAXALTA INNOVATIONS GMBH
2019 Phase 3 EUCTR2017-000858-18-IT Austria;Canada;France;Germany;Italy;Japan;Poland;Spain;Switzerland;United Kingdom;United States;
Baxalta Innovations GmbH
2019 Phase 3 EUCTR2017-000858-18-DE Austria;Canada;France;Germany;Italy;Japan;Poland;Spain;Switzerland;United Kingdom;United States;
2018 Phase 3 EUCTR2017-000858-18-AT Austria;Canada;France;Germany;Italy;Japan;Poland;Spain;Switzerland;United Kingdom;United States;
2017 Phase 3 EUCTR2017-000858-18-GB Austria;Canada;France;Germany;Italy;Japan;Poland;Spain;Switzerland;United Kingdom;United States;
2017 Phase 3 EUCTR2017-000858-18-ES Austria;Canada;France;Germany;Italy;Japan;Poland;Spain;Switzerland;United Kingdom;United States;
2015 Phase 1 EUCTR2012-003221-19-DE Austria;Germany;Japan;Poland;Switzerland;United Kingdom;United States;
2015 - EUCTR2012-003221-19-PL Austria;Germany;Japan;Poland;Switzerland;United Kingdom;United States;
2013 Phase 1 EUCTR2012-003221-19-GB Austria;Germany;Japan;Poland;United Kingdom;United States;
2012 - EUCTR2012-003221-19-AT Austria;Germany;Japan;Poland;United Kingdom;United States;
- Phase 3 EUCTR2017-000858-18-PL Austria;Canada;France;Germany;Italy;Japan;Poland;Spain;Switzerland;United Kingdom;United States;
- Phase 3 EUCTR2017-000858-18-FR Austria;Canada;France;Germany;Italy;Japan;Poland;Spain;Switzerland;United Kingdom;United States;
Recombinant ADAMTS13
Baxalta now part of Shire
2014 Phase 1 NCT02216084 Austria;Germany;Japan;Poland;Switzerland;United Kingdom;United States;
Rituximab
Assistance Publique - Hôpitaux de Paris
2010 Phase 2 NCT00907751 France;
David Gomez Almaguer
2020 Phase 2 NCT04588194 Mexico;
FONDAZIONE IRCCS CA` GRANDA OSPEDALE MAGGIORE POLICLINICO DI MILANO
2010 - EUCTR2010-018794-38-IT Italy;
Hamilton Health Sciences Corporation
2007 Phase 2 NCT00531089 Canada;
New England Research Institutes
2009 Phase 3 NCT00799773 United States;
Saitama Medical University , Department of General Internal Medicine, Yoshitaka Miyakawa
2014 Phase 2 JPRN-JMA-IIA00160 Japan;
The First Affiliated Hospital Of Soochow University
2013 Phase 1 study ChiCTR-ONRC-13003194 China;
University College, London
2006 Phase 2 NCT00937131 United Kingdom;
Washington University School of Medicine
2012 Phase 2 NCT01554514 United States;
Weill Medical College of Cornell University
2005 Phase 1/Phase 2 NCT00251277 United States;
Romiplostim
David Gomez Almaguer
2020 Phase 2 NCT04588194 Mexico;
SHP 655 (BAX 930)
BAXALTA INNOVATIONS GMBH
2020 Phase 2 EUCTR2018-003775-35-IT Canada;France;Germany;Italy;Netherlands;Spain;Switzerland;United Kingdom;United States;
Baxalta Innovation GmbH
2019 Phase 2 EUCTR2018-003775-35-DE Canada;France;Germany;Italy;Netherlands;Spain;Switzerland;United Kingdom;United States;
Baxalta Innovations GmbH
2019 Phase 2 EUCTR2018-003775-35-GB Canada;France;Germany;Italy;Spain;United Kingdom;United States;
2019 Phase 2 EUCTR2018-003775-35-ES Canada;France;Germany;Italy;Netherlands;Spain;Switzerland;United Kingdom;United States;
SHP655
Shire
2019 Phase 2 NCT03922308 Canada;France;Germany;Italy;Spain;United Kingdom;United States;
Standard Plasma
Octapharma
2017 - NCT01938404 United States;
Standard of care
Baxalta now part of Shire
2017 Phase 3 NCT03393975 Austria;France;Germany;Italy;Japan;Poland;Spain;Switzerland;United Kingdom;United States;
Standrd of Care treatment
Baxalta now part of Shire(ICCC: IQVIA Services Japan K.K.)
2019 Phase 3 JPRN-JapicCTI-194991 Japan, North America, Europe;
Sulfate, Magnesium
Assistance Publique - Hôpitaux de Paris
2018 Phase 3 NCT03237819 France;
TAK-755
Takeda
2021 Phase 3 NCT04683003 Austria;France;Germany;Italy;Japan;Poland;Spain;Switzerland;United Kingdom;United States;
TAK-755 or BAX930 or SHP655
Baxalta Innovations GmbH
- Phase 3 EUCTR2020-003348-10-FR Australia;Austria;Belgium;Brazil;Canada;China;Colombia;Czechia;Denmark;France;Germany;Hungary;India;Israel;Italy;Japan;Korea, Republic of;Netherlands;Norway;Poland;Portugal;Russian Federation;Serbia;Spain;Sweden;Switzerland;Taiwan;Thailand;Turkey;Ukraine;United Kingdom;United States;
TAK-755 orBAX930 or SHP655
BAXALTA INNOVATIONS GMBH
2022 Phase 3 EUCTR2020-003348-10-IT Australia;Austria;Belgium;Brazil;Canada;China;Colombia;Czechia;Denmark;France;Germany;Hungary;India;Israel;Italy;Japan;Korea, Republic of;Netherlands;Norway;Poland;Portugal;Russian Federation;Serbia;Spain;Sweden;Switzerland;Taiwan;Thailand;Turkey;Ukraine;United Kingdom;United States;
Baxalta Innovations GmbH
2020 Phase 3 EUCTR2020-003348-10-GB Australia;Austria;Belgium;Brazil;Canada;China;Colombia;Czechia;Denmark;France;Germany;Hungary;India;Israel;Italy;Japan;Korea, Republic of;Netherlands;Norway;Poland;Portugal;Russian Federation;Serbia;Spain;Sweden;Switzerland;Taiwan;Thailand;Turkey;Ukraine;United Kingdom;United States;
- Phase 3 EUCTR2020-003348-10-PL Australia;Austria;Belgium;Brazil;Canada;China;Colombia;Czechia;Denmark;France;Germany;Hungary;India;Israel;Italy;Japan;Korea, Republic of;Netherlands;Norway;Poland;Portugal;Russian Federation;Serbia;Spain;Sweden;Switzerland;Taiwan;Thailand;Turkey;Ukraine;United Kingdom;United States;
- Phase 3 EUCTR2020-003348-10-AT Australia;Austria;Belgium;Brazil;Canada;China;Colombia;Czechia;Denmark;France;Germany;Hungary;India;Israel;Italy;Japan;Korea, Republic of;Netherlands;Norway;Poland;Portugal;Russian Federation;Serbia;Spain;Sweden;Switzerland;Taiwan;Thailand;Turkey;Ukraine;United Kingdom;United States;
Uniplas
Octapharma
2007 Phase 3 NCT00411801 United States;
ABLYNX N.V.
2010 - EUCTR2010-019375-30-IT Austria;Belgium;Germany;Italy;Spain;United Kingdom;
ABLYNX NV
- Phase 3 EUCTR2015-001098-42-IT Australia;Austria;Belgium;Canada;Czech Republic;Czechia;France;Germany;Hungary;Israel;Italy;Netherlands;New Zealand;Spain;Switzerland;Turkey;United Kingdom;United States;
Ablynx
2011 - EUCTR2010-019375-30-ES Austria;Belgium;Germany;Italy;Spain;United Kingdom;
2010 Phase 2 EUCTR2010-019375-30-GB Austria;Belgium;Canada;Germany;Israel;Italy;Russian Federation;Spain;Switzerland;United Kingdom;United States;
2010 Phase 2 EUCTR2010-019375-30-BE Australia;Austria;Belgium;Germany;Israel;Italy;Spain;Switzerland;United Kingdom;United States;
2010 - EUCTR2010-019375-30-DE Austria;Belgium;Canada;Germany;Israel;Italy;Russian Federation;Spain;Switzerland;United Kingdom;United States;
2010 - EUCTR2010-019375-30-AT Austria;Belgium;Canada;Germany;Israel;Italy;Russian Federation;Spain;Switzerland;United Kingdom;United States;
Ablynx NV
2016 Phase 3 EUCTR2015-001098-42-NL Australia;Austria;Belgium;Canada;Czech Republic;France;Germany;Hungary;Israel;Italy;Netherlands;New Zealand;Spain;Switzerland;Turkey;United Kingdom;United States;
2015 Phase 3 EUCTR2015-001098-42-HU Australia;Austria;Belgium;Canada;Czech Republic;France;Germany;Hungary;Israel;Italy;Netherlands;Spain;Switzerland;Turkey;United Kingdom;United States;
2015 Phase 3 EUCTR2015-001098-42-ES Australia;Austria;Belgium;Canada;Czech Republic;France;Germany;Hungary;Israel;Italy;Netherlands;New Zealand;Spain;Switzerland;Turkey;United Kingdom;United States;
2015 Phase 3 EUCTR2015-001098-42-DE Australia;Austria;Belgium;Canada;Czech Republic;France;Germany;Hungary;Israel;Italy;Netherlands;New Zealand;Spain;Switzerland;Turkey;United Kingdom;United States;
2015 Phase 3 EUCTR2015-001098-42-CZ Australia;Austria;Belgium;Canada;Czech Republic;France;Germany;Hungary;Israel;Italy;Netherlands;Spain;Switzerland;Turkey;United Kingdom;United States;
2015 Phase 3 EUCTR2015-001098-42-BE Australia;Austria;Belgium;Canada;Czech Republic;France;Germany;Hungary;Israel;Italy;Netherlands;New Zealand;Spain;Switzerland;Turkey;United Kingdom;United States;
2015 Phase 3 EUCTR2015-001098-42-AT Australia;Austria;Belgium;Canada;Czech Republic;France;Germany;Hungary;Israel;Italy;Netherlands;Spain;Switzerland;Turkey;United Kingdom;United States;
- Phase 3 EUCTR2015-001098-42-Outside-EU/EEA Australia;Canada;Israel;Switzerland;Turkey;United States;
ARC 1779
Archemix Corp.
2007 - EUCTR2007-004371-19-AT Austria;
ARC1779 Injection
Archemix Corp.
2008 Phase 2 NCT00726544 Austria;Canada;Italy;United Kingdom;United States;
2007 - EUCTR2007-004371-19-AT Austria;
Anfibatide
Lee's Pharmaceutical Limited
2019 Phase 2 NCT04021173 China;
Anti-von Willebrand Factor Nanobody
ABLYNX N.V.
2010 - EUCTR2010-019375-30-IT Austria;Belgium;Germany;Italy;Spain;United Kingdom;
Ablynx
2011 - EUCTR2010-019375-30-ES Austria;Belgium;Germany;Italy;Spain;United Kingdom;
Anti-von Willebrand Factor Nanobody, Caplacizumab
Ablynx
2010 - EUCTR2010-019375-30-DE Austria;Belgium;Canada;Germany;Israel;Italy;Russian Federation;Spain;Switzerland;United Kingdom;United States;
2010 - EUCTR2010-019375-30-AT Austria;Belgium;Canada;Germany;Israel;Italy;Russian Federation;Spain;Switzerland;United Kingdom;United States;
Anti-von Willebrand Factor Nanobody, INN = Caplacizumab
Ablynx
2010 Phase 2 EUCTR2010-019375-30-GB Austria;Belgium;Canada;Germany;Israel;Italy;Russian Federation;Spain;Switzerland;United Kingdom;United States;
2010 Phase 2 EUCTR2010-019375-30-BE Australia;Austria;Belgium;Germany;Israel;Italy;Spain;Switzerland;United Kingdom;United States;
Apadamtase alfa
BAXALTA INNOVATIONS GMBH
2022 Phase 3 EUCTR2020-003348-10-IT Australia;Austria;Belgium;Brazil;Canada;China;Colombia;Czechia;Denmark;France;Germany;Hungary;India;Israel;Italy;Japan;Korea, Republic of;Netherlands;Norway;Poland;Portugal;Russian Federation;Serbia;Spain;Sweden;Switzerland;Taiwan;Thailand;Turkey;Ukraine;United Kingdom;United States;
2020 Phase 2 EUCTR2018-003775-35-IT Canada;France;Germany;Italy;Netherlands;Spain;Switzerland;United Kingdom;United States;
2019 Phase 3 EUCTR2017-000858-18-IT Austria;Canada;France;Germany;Italy;Japan;Poland;Spain;Switzerland;United Kingdom;United States;
Baxalta Innovation GmbH
2019 Phase 2 EUCTR2018-003775-35-DE Canada;France;Germany;Italy;Netherlands;Spain;Switzerland;United Kingdom;United States;
Baxalta Innovations GmbH
2020 Phase 3 EUCTR2020-003348-10-GB Australia;Austria;Belgium;Brazil;Canada;China;Colombia;Czechia;Denmark;France;Germany;Hungary;India;Israel;Italy;Japan;Korea, Republic of;Netherlands;Norway;Poland;Portugal;Russian Federation;Serbia;Spain;Sweden;Switzerland;Taiwan;Thailand;Turkey;Ukraine;United Kingdom;United States;
2019 Phase 3 EUCTR2017-000858-18-DE Austria;Canada;France;Germany;Italy;Japan;Poland;Spain;Switzerland;United Kingdom;United States;
2019 Phase 2 EUCTR2018-003775-35-GB Canada;France;Germany;Italy;Spain;United Kingdom;United States;
2019 Phase 2 EUCTR2018-003775-35-ES Canada;France;Germany;Italy;Netherlands;Spain;Switzerland;United Kingdom;United States;
2018 Phase 3 EUCTR2017-000858-18-AT Austria;Canada;France;Germany;Italy;Japan;Poland;Spain;Switzerland;United Kingdom;United States;
2017 Phase 3 EUCTR2017-000858-18-GB Austria;Canada;France;Germany;Italy;Japan;Poland;Spain;Switzerland;United Kingdom;United States;
2017 Phase 3 EUCTR2017-000858-18-ES Austria;Canada;France;Germany;Italy;Japan;Poland;Spain;Switzerland;United Kingdom;United States;
- Phase 3 EUCTR2020-003348-10-PL Australia;Austria;Belgium;Brazil;Canada;China;Colombia;Czechia;Denmark;France;Germany;Hungary;India;Israel;Italy;Japan;Korea, Republic of;Netherlands;Norway;Poland;Portugal;Russian Federation;Serbia;Spain;Sweden;Switzerland;Taiwan;Thailand;Turkey;Ukraine;United Kingdom;United States;
- Phase 3 EUCTR2020-003348-10-FR Australia;Austria;Belgium;Brazil;Canada;China;Colombia;Czechia;Denmark;France;Germany;Hungary;India;Israel;Italy;Japan;Korea, Republic of;Netherlands;Norway;Poland;Portugal;Russian Federation;Serbia;Spain;Sweden;Switzerland;Taiwan;Thailand;Turkey;Ukraine;United Kingdom;United States;
- Phase 3 EUCTR2020-003348-10-AT Australia;Austria;Belgium;Brazil;Canada;China;Colombia;Czechia;Denmark;France;Germany;Hungary;India;Israel;Italy;Japan;Korea, Republic of;Netherlands;Norway;Poland;Portugal;Russian Federation;Serbia;Spain;Sweden;Switzerland;Taiwan;Thailand;Turkey;Ukraine;United Kingdom;United States;
- Phase 3 EUCTR2017-000858-18-PL Austria;Canada;France;Germany;Italy;Japan;Poland;Spain;Switzerland;United Kingdom;United States;
- Phase 3 EUCTR2017-000858-18-FR Austria;Canada;France;Germany;Italy;Japan;Poland;Spain;Switzerland;United Kingdom;United States;
Apademtase alfa
Baxalta Innovations GmbH
2018 Phase 3 EUCTR2017-000858-18-AT Austria;Canada;France;Germany;Italy;Japan;Poland;Spain;Switzerland;United Kingdom;United States;
BAX930
Baxalta Innovations GmbH
2015 Phase 1 EUCTR2012-003221-19-DE Austria;Germany;Japan;Poland;Switzerland;United Kingdom;United States;
2015 - EUCTR2012-003221-19-PL Austria;Germany;Japan;Poland;Switzerland;United Kingdom;United States;
2013 Phase 1 EUCTR2012-003221-19-GB Austria;Germany;Japan;Poland;United Kingdom;United States;
2012 - EUCTR2012-003221-19-AT Austria;Germany;Japan;Poland;United Kingdom;United States;
Baxalta now part of Shire
2017 Phase 3 NCT03393975 Austria;France;Germany;Italy;Japan;Poland;Spain;Switzerland;United Kingdom;United States;
BAX930 - RECOMBINANT HUMAN ADAMTS13
BAXALTA INNOVATIONS GMBH
2020 Phase 2 EUCTR2018-003775-35-IT Canada;France;Germany;Italy;Netherlands;Spain;Switzerland;United Kingdom;United States;
Baxalta Innovation GmbH
2019 Phase 2 EUCTR2018-003775-35-DE Canada;France;Germany;Italy;Netherlands;Spain;Switzerland;United Kingdom;United States;
Baxalta Innovations GmbH
2019 Phase 2 EUCTR2018-003775-35-GB Canada;France;Germany;Italy;Spain;United Kingdom;United States;
2019 Phase 2 EUCTR2018-003775-35-ES Canada;France;Germany;Italy;Netherlands;Spain;Switzerland;United Kingdom;United States;
BAX930 or SHP655
BAXALTA INNOVATIONS GMBH
2019 Phase 3 EUCTR2017-000858-18-IT Austria;Canada;France;Germany;Italy;Japan;Poland;Spain;Switzerland;United Kingdom;United States;
Baxalta Innovations GmbH
2019 Phase 3 EUCTR2017-000858-18-DE Austria;Canada;France;Germany;Italy;Japan;Poland;Spain;Switzerland;United Kingdom;United States;
2018 Phase 3 EUCTR2017-000858-18-AT Austria;Canada;France;Germany;Italy;Japan;Poland;Spain;Switzerland;United Kingdom;United States;
2017 Phase 3 EUCTR2017-000858-18-GB Austria;Canada;France;Germany;Italy;Japan;Poland;Spain;Switzerland;United Kingdom;United States;
2017 Phase 3 EUCTR2017-000858-18-ES Austria;Canada;France;Germany;Italy;Japan;Poland;Spain;Switzerland;United Kingdom;United States;
- Phase 3 EUCTR2017-000858-18-PL Austria;Canada;France;Germany;Italy;Japan;Poland;Spain;Switzerland;United Kingdom;United States;
- Phase 3 EUCTR2017-000858-18-FR Austria;Canada;France;Germany;Italy;Japan;Poland;Spain;Switzerland;United Kingdom;United States;
Bortezomib Injection
Peking Union Medical College Hospital
2021 Phase 4 NCT05135442 China;
Cablivi®
University of Cologne
2021 - NCT04985318 Germany;
Caplacizumab
Ablynx
2015 Phase 3 NCT02553317 Australia;Austria;Belgium;Canada;Czech Republic;Czechia;France;Germany;Hungary;Israel;Italy;Netherlands;Spain;Switzerland;Turkey;United Kingdom;United States;
2011 Phase 2 NCT01151423 Australia;Austria;Belgium;Bulgaria;France;Germany;Israel;Italy;Romania;Spain;Switzerland;United Kingdom;United States;
Ablynx NV
2016 Phase 3 EUCTR2015-001098-42-NL Australia;Austria;Belgium;Canada;Czech Republic;France;Germany;Hungary;Israel;Italy;Netherlands;New Zealand;Spain;Switzerland;Turkey;United Kingdom;United States;
2015 Phase 3 EUCTR2015-001098-42-CZ Australia;Austria;Belgium;Canada;Czech Republic;France;Germany;Hungary;Israel;Italy;Netherlands;Spain;Switzerland;Turkey;United Kingdom;United States;
- Phase 3 EUCTR2015-001098-42-Outside-EU/EEA Australia;Canada;Israel;Switzerland;Turkey;United States;
Sanofi
2022 - NCT05263193 France;
2016 Phase 3 NCT02878603 Austria;Belgium;Canada;Czech Republic;Czechia;France;Hungary;Israel;Italy;Spain;Switzerland;Turkey;United Kingdom;United States;
University Hospital, Rouen
2021 Phase 2 NCT04720261 -
Caplacizumab (ALX-0081)
Sanofi
2019 Phase 2/Phase 3 NCT04074187 Japan;
Caplacizumab (an anti-von Willebrand Factor Nanobody ALX-0081)
ABLYNX NV
- Phase 3 EUCTR2016-001503-23-IT Austria;Belgium;Canada;Czech Republic;Czechia;France;Germany;Hungary;Israel;Italy;Netherlands;Spain;Switzerland;Turkey;United Kingdom;United States;
Ablynx NV
2017 Phase 3 EUCTR2016-001503-23-NL Australia;Austria;Belgium;Canada;Czech Republic;France;Germany;Hungary;Israel;Italy;Netherlands;Spain;Switzerland;Turkey;United Kingdom;United States;
2017 Phase 3 EUCTR2016-001503-23-FR Australia;Austria;Belgium;Canada;Czech Republic;France;Germany;Hungary;Israel;Italy;Netherlands;Spain;Switzerland;Turkey;United Kingdom;United States;
2017 Phase 3 EUCTR2016-001503-23-DE Australia;Austria;Belgium;Canada;Czech Republic;France;Germany;Hungary;Israel;Italy;Netherlands;Spain;Switzerland;Turkey;United Kingdom;United States;
2016 Phase 3 EUCTR2016-001503-23-HU Australia;Austria;Belgium;Canada;Czech Republic;France;Germany;Hungary;Israel;Italy;Netherlands;Spain;Switzerland;Turkey;United Kingdom;United States;
2016 Phase 3 EUCTR2016-001503-23-GB Austria;Belgium;Canada;Czech Republic;France;Germany;Hungary;Israel;Italy;Netherlands;Spain;Switzerland;Turkey;United Kingdom;United States;
2016 Phase 3 EUCTR2016-001503-23-ES Australia;Austria;Belgium;Canada;Czech Republic;France;Germany;Hungary;Israel;Italy;Netherlands;Spain;Switzerland;Turkey;United Kingdom;United States;
2016 Phase 3 EUCTR2016-001503-23-CZ Austria;Belgium;Canada;Czech Republic;France;Germany;Hungary;Israel;Italy;Netherlands;Spain;Switzerland;Turkey;United Kingdom;United States;
2016 Phase 3 EUCTR2016-001503-23-BE Austria;Belgium;Canada;Czech Republic;France;Germany;Hungary;Israel;Italy;Netherlands;Spain;Switzerland;Turkey;United Kingdom;United States;
2016 Phase 3 EUCTR2016-001503-23-AT Austria;Belgium;Canada;Czech Republic;France;Germany;Hungary;Israel;Italy;Netherlands;Spain;Switzerland;Turkey;United Kingdom;United States;
Caplacizumab (an anti-von Willebrand Factor Nanobody)
ABLYNX NV
- Phase 3 EUCTR2015-001098-42-IT Australia;Austria;Belgium;Canada;Czech Republic;Czechia;France;Germany;Hungary;Israel;Italy;Netherlands;New Zealand;Spain;Switzerland;Turkey;United Kingdom;United States;
Ablynx NV
2015 Phase 3 EUCTR2015-001098-42-HU Australia;Austria;Belgium;Canada;Czech Republic;France;Germany;Hungary;Israel;Italy;Netherlands;Spain;Switzerland;Turkey;United Kingdom;United States;
2015 Phase 3 EUCTR2015-001098-42-ES Australia;Austria;Belgium;Canada;Czech Republic;France;Germany;Hungary;Israel;Italy;Netherlands;New Zealand;Spain;Switzerland;Turkey;United Kingdom;United States;
2015 Phase 3 EUCTR2015-001098-42-DE Australia;Austria;Belgium;Canada;Czech Republic;France;Germany;Hungary;Israel;Italy;Netherlands;New Zealand;Spain;Switzerland;Turkey;United Kingdom;United States;
2015 Phase 3 EUCTR2015-001098-42-BE Australia;Austria;Belgium;Canada;Czech Republic;France;Germany;Hungary;Israel;Italy;Netherlands;New Zealand;Spain;Switzerland;Turkey;United Kingdom;United States;
2015 Phase 3 EUCTR2015-001098-42-AT Australia;Austria;Belgium;Canada;Czech Republic;France;Germany;Hungary;Israel;Italy;Netherlands;Spain;Switzerland;Turkey;United Kingdom;United States;
Corticosteroid treatment (Methylprednisolone or prednisolone)
Sanofi
2019 Phase 2/Phase 3 NCT04074187 Japan;
Corticosteroids
New England Research Institutes
2009 Phase 3 NCT00799773 United States;
Cryosupernatant plasma
Octapharma
2007 Phase 3 NCT00411801 United States;
Cyclosporine
Ohio State University
2007 Phase 3 NCT00713193 United States;
Danazol
Icahn School of Medicine at Mount Sinai
2008 Phase 2 NCT00953771 United States;
Desmopressin acetate
Archemix Corp.
2007 - EUCTR2007-004371-19-AT Austria;
Dexamethasone
David Gomez Almaguer
2020 Phase 2 NCT04588194 Mexico;
HMED-IdeS
Hansa Medical AB
2016 Phase 2 EUCTR2016-000249-30-GB United Kingdom;
IDEC-C2B8, Ro 45-2294
University College London
2005 Phase 2 EUCTR2005-002274-30-GB United Kingdom;
IdeS (0.25 mg/kg)
Hansa Biopharma AB
2016 Phase 2 NCT02854059 United Kingdom;
IdeS (0.50 mg/kg)
Hansa Biopharma AB
2016 Phase 2 NCT02854059 United Kingdom;
Immunosuppressive treatment (eg, rituximab)
Sanofi
2019 Phase 2/Phase 3 NCT04074187 Japan;
MabThera
University College London
2005 Phase 2 EUCTR2005-002274-30-GB United Kingdom;
Minirin
Archemix Corp.
2007 - EUCTR2007-004371-19-AT Austria;
OMS721 100 mg/ml Injection solution, OMS00620646, OMS620646, MASP-2 Antibody
Omeros Corporation
2014 Phase 2 EUCTR2014-001032-11-PL Belgium;Bulgaria;Hong Kong;Italy;Lithuania;Malaysia;New Zealand;Poland;Singapore;Taiwan;Thailand;United States;
2014 Phase 2 EUCTR2014-001032-11-LT Belgium;Bulgaria;Hong Kong;Italy;Lithuania;Malaysia;New Zealand;Poland;Singapore;Taiwan;Thailand;United States;
2014 Phase 2 EUCTR2014-001032-11-BE Belarus;Belgium;Bulgaria;Germany;Hong Kong;Italy;Lithuania;Malaysia;New Zealand;Poland;Switzerland;Taiwan;Thailand;Turkey;United Kingdom;United States;
OMS721 185 mg/ml Injection solution, OMS00620646, OMS620646, MASP-2 Antibody
Omeros Corporation
2014 Phase 2 EUCTR2014-001032-11-PL Belgium;Bulgaria;Hong Kong;Italy;Lithuania;Malaysia;New Zealand;Poland;Singapore;Taiwan;Thailand;United States;
2014 Phase 2 EUCTR2014-001032-11-LT Belgium;Bulgaria;Hong Kong;Italy;Lithuania;Malaysia;New Zealand;Poland;Singapore;Taiwan;Thailand;United States;
Octaplas
Octapharma
2017 - NCT01938404 United States;
Octaplas SD
Baxalta Innovations GmbH
2018 Phase 3 EUCTR2017-000858-18-AT Austria;Canada;France;Germany;Italy;Japan;Poland;Spain;Switzerland;United Kingdom;United States;
Octaplas infusion
St. Olavs Hospital
2012 Phase 4 NCT01754545 Norway;
OctaplasLG®
Octapharma
2018 - NCT03369314 France;New Caledonia;
Octaplas®LG
Baxalta Innovations GmbH
2018 Phase 3 EUCTR2017-000858-18-AT Austria;Canada;France;Germany;Italy;Japan;Poland;Spain;Switzerland;United Kingdom;United States;
Octostim
Archemix Corp.
2007 - EUCTR2007-004371-19-AT Austria;
Plasma exchange
New England Research Institutes
2009 Phase 3 NCT00799773 United States;
Plasma exchange (PE)
Sanofi
2019 Phase 2/Phase 3 NCT04074187 Japan;
Pooled Plasma (Human), Solvent/Detergent Treated
Baxalta Innovations GmbH
2018 Phase 3 EUCTR2017-000858-18-AT Austria;Canada;France;Germany;Italy;Japan;Poland;Spain;Switzerland;United Kingdom;United States;
Prednisone
Ohio State University
2007 Phase 3 NCT00713193 United States;
RADAMTS-13
Baxalta now part of Shire(ICCC: IQVIA Services Japan K.K.)
2019 Phase 3 JPRN-JapicCTI-194991 Japan, North America, Europe;
Recombinant A Disintegrin And Metalloproteinase with Thrombospondin Type-1 Motifs 13 (rADAMTS13)
BAXALTA INNOVATIONS GMBH
2020 Phase 2 EUCTR2018-003775-35-IT Canada;France;Germany;Italy;Netherlands;Spain;Switzerland;United Kingdom;United States;
Baxalta Innovation GmbH
2019 Phase 2 EUCTR2018-003775-35-DE Canada;France;Germany;Italy;Netherlands;Spain;Switzerland;United Kingdom;United States;
Baxalta Innovations GmbH
2019 Phase 2 EUCTR2018-003775-35-GB Canada;France;Germany;Italy;Spain;United Kingdom;United States;
2019 Phase 2 EUCTR2018-003775-35-ES Canada;France;Germany;Italy;Netherlands;Spain;Switzerland;United Kingdom;United States;
Recombinant A Disintegrin and Metalloproteinase Thrombospondin Type-1 Motifs 13
BAXALTA INNOVATIONS GMBH
2022 Phase 3 EUCTR2020-003348-10-IT Australia;Austria;Belgium;Brazil;Canada;China;Colombia;Czechia;Denmark;France;Germany;Hungary;India;Israel;Italy;Japan;Korea, Republic of;Netherlands;Norway;Poland;Portugal;Russian Federation;Serbia;Spain;Sweden;Switzerland;Taiwan;Thailand;Turkey;Ukraine;United Kingdom;United States;
Baxalta Innovations GmbH
2020 Phase 3 EUCTR2020-003348-10-GB Australia;Austria;Belgium;Brazil;Canada;China;Colombia;Czechia;Denmark;France;Germany;Hungary;India;Israel;Italy;Japan;Korea, Republic of;Netherlands;Norway;Poland;Portugal;Russian Federation;Serbia;Spain;Sweden;Switzerland;Taiwan;Thailand;Turkey;Ukraine;United Kingdom;United States;
- Phase 3 EUCTR2020-003348-10-PL Australia;Austria;Belgium;Brazil;Canada;China;Colombia;Czechia;Denmark;France;Germany;Hungary;India;Israel;Italy;Japan;Korea, Republic of;Netherlands;Norway;Poland;Portugal;Russian Federation;Serbia;Spain;Sweden;Switzerland;Taiwan;Thailand;Turkey;Ukraine;United Kingdom;United States;
- Phase 3 EUCTR2020-003348-10-FR Australia;Austria;Belgium;Brazil;Canada;China;Colombia;Czechia;Denmark;France;Germany;Hungary;India;Israel;Italy;Japan;Korea, Republic of;Netherlands;Norway;Poland;Portugal;Russian Federation;Serbia;Spain;Sweden;Switzerland;Taiwan;Thailand;Turkey;Ukraine;United Kingdom;United States;
- Phase 3 EUCTR2020-003348-10-AT Australia;Austria;Belgium;Brazil;Canada;China;Colombia;Czechia;Denmark;France;Germany;Hungary;India;Israel;Italy;Japan;Korea, Republic of;Netherlands;Norway;Poland;Portugal;Russian Federation;Serbia;Spain;Sweden;Switzerland;Taiwan;Thailand;Turkey;Ukraine;United Kingdom;United States;
Recombinant A Disintegrin and Metalloproteinase with Thrombospondin Type-1 Motifs
Baxalta Innovations GmbH
2020 Phase 3 EUCTR2020-003348-10-GB Australia;Austria;Belgium;Brazil;Canada;China;Colombia;Czechia;Denmark;France;Germany;Hungary;India;Israel;Italy;Japan;Korea, Republic of;Netherlands;Norway;Poland;Portugal;Russian Federation;Serbia;Spain;Sweden;Switzerland;Taiwan;Thailand;Turkey;Ukraine;United Kingdom;United States;
- Phase 3 EUCTR2020-003348-10-PL Australia;Austria;Belgium;Brazil;Canada;China;Colombia;Czechia;Denmark;France;Germany;Hungary;India;Israel;Italy;Japan;Korea, Republic of;Netherlands;Norway;Poland;Portugal;Russian Federation;Serbia;Spain;Sweden;Switzerland;Taiwan;Thailand;Turkey;Ukraine;United Kingdom;United States;
- Phase 3 EUCTR2020-003348-10-FR Australia;Austria;Belgium;Brazil;Canada;China;Colombia;Czechia;Denmark;France;Germany;Hungary;India;Israel;Italy;Japan;Korea, Republic of;Netherlands;Norway;Poland;Portugal;Russian Federation;Serbia;Spain;Sweden;Switzerland;Taiwan;Thailand;Turkey;Ukraine;United Kingdom;United States;
- Phase 3 EUCTR2020-003348-10-AT Australia;Austria;Belgium;Brazil;Canada;China;Colombia;Czechia;Denmark;France;Germany;Hungary;India;Israel;Italy;Japan;Korea, Republic of;Netherlands;Norway;Poland;Portugal;Russian Federation;Serbia;Spain;Sweden;Switzerland;Taiwan;Thailand;Turkey;Ukraine;United Kingdom;United States;
Recombinant A Disintegrin and Metalloproteinase with Thrombospondin Type-1 Motifs 13
BAXALTA INNOVATIONS GMBH
2019 Phase 3 EUCTR2017-000858-18-IT Austria;Canada;France;Germany;Italy;Japan;Poland;Spain;Switzerland;United Kingdom;United States;
Baxalta Innovations GmbH
2019 Phase 3 EUCTR2017-000858-18-DE Austria;Canada;France;Germany;Italy;Japan;Poland;Spain;Switzerland;United Kingdom;United States;
2018 Phase 3 EUCTR2017-000858-18-AT Austria;Canada;France;Germany;Italy;Japan;Poland;Spain;Switzerland;United Kingdom;United States;
2017 Phase 3 EUCTR2017-000858-18-GB Austria;Canada;France;Germany;Italy;Japan;Poland;Spain;Switzerland;United Kingdom;United States;
2017 Phase 3 EUCTR2017-000858-18-ES Austria;Canada;France;Germany;Italy;Japan;Poland;Spain;Switzerland;United Kingdom;United States;
2015 Phase 1 EUCTR2012-003221-19-DE Austria;Germany;Japan;Poland;Switzerland;United Kingdom;United States;
2015 - EUCTR2012-003221-19-PL Austria;Germany;Japan;Poland;Switzerland;United Kingdom;United States;
2013 Phase 1 EUCTR2012-003221-19-GB Austria;Germany;Japan;Poland;United Kingdom;United States;
2012 - EUCTR2012-003221-19-AT Austria;Germany;Japan;Poland;United Kingdom;United States;
- Phase 3 EUCTR2017-000858-18-PL Austria;Canada;France;Germany;Italy;Japan;Poland;Spain;Switzerland;United Kingdom;United States;
- Phase 3 EUCTR2017-000858-18-FR Austria;Canada;France;Germany;Italy;Japan;Poland;Spain;Switzerland;United Kingdom;United States;
Recombinant ADAMTS13
Baxalta now part of Shire
2014 Phase 1 NCT02216084 Austria;Germany;Japan;Poland;Switzerland;United Kingdom;United States;
Rituximab
Assistance Publique - Hôpitaux de Paris
2010 Phase 2 NCT00907751 France;
David Gomez Almaguer
2020 Phase 2 NCT04588194 Mexico;
FONDAZIONE IRCCS CA` GRANDA OSPEDALE MAGGIORE POLICLINICO DI MILANO
2010 - EUCTR2010-018794-38-IT Italy;
Hamilton Health Sciences Corporation
2007 Phase 2 NCT00531089 Canada;
New England Research Institutes
2009 Phase 3 NCT00799773 United States;
Saitama Medical University , Department of General Internal Medicine, Yoshitaka Miyakawa
2014 Phase 2 JPRN-JMA-IIA00160 Japan;
The First Affiliated Hospital Of Soochow University
2013 Phase 1 study ChiCTR-ONRC-13003194 China;
University College, London
2006 Phase 2 NCT00937131 United Kingdom;
Washington University School of Medicine
2012 Phase 2 NCT01554514 United States;
Weill Medical College of Cornell University
2005 Phase 1/Phase 2 NCT00251277 United States;
Romiplostim
David Gomez Almaguer
2020 Phase 2 NCT04588194 Mexico;
SHP 655 (BAX 930)
BAXALTA INNOVATIONS GMBH
2020 Phase 2 EUCTR2018-003775-35-IT Canada;France;Germany;Italy;Netherlands;Spain;Switzerland;United Kingdom;United States;
Baxalta Innovation GmbH
2019 Phase 2 EUCTR2018-003775-35-DE Canada;France;Germany;Italy;Netherlands;Spain;Switzerland;United Kingdom;United States;
Baxalta Innovations GmbH
2019 Phase 2 EUCTR2018-003775-35-GB Canada;France;Germany;Italy;Spain;United Kingdom;United States;
2019 Phase 2 EUCTR2018-003775-35-ES Canada;France;Germany;Italy;Netherlands;Spain;Switzerland;United Kingdom;United States;
SHP655
Shire
2019 Phase 2 NCT03922308 Canada;France;Germany;Italy;Spain;United Kingdom;United States;
Standard Plasma
Octapharma
2017 - NCT01938404 United States;
Standard of care
Baxalta now part of Shire
2017 Phase 3 NCT03393975 Austria;France;Germany;Italy;Japan;Poland;Spain;Switzerland;United Kingdom;United States;
Standrd of Care treatment
Baxalta now part of Shire(ICCC: IQVIA Services Japan K.K.)
2019 Phase 3 JPRN-JapicCTI-194991 Japan, North America, Europe;
Sulfate, Magnesium
Assistance Publique - Hôpitaux de Paris
2018 Phase 3 NCT03237819 France;
TAK-755
Takeda
2021 Phase 3 NCT04683003 Austria;France;Germany;Italy;Japan;Poland;Spain;Switzerland;United Kingdom;United States;
TAK-755 or BAX930 or SHP655
Baxalta Innovations GmbH
- Phase 3 EUCTR2020-003348-10-FR Australia;Austria;Belgium;Brazil;Canada;China;Colombia;Czechia;Denmark;France;Germany;Hungary;India;Israel;Italy;Japan;Korea, Republic of;Netherlands;Norway;Poland;Portugal;Russian Federation;Serbia;Spain;Sweden;Switzerland;Taiwan;Thailand;Turkey;Ukraine;United Kingdom;United States;
TAK-755 orBAX930 or SHP655
BAXALTA INNOVATIONS GMBH
2022 Phase 3 EUCTR2020-003348-10-IT Australia;Austria;Belgium;Brazil;Canada;China;Colombia;Czechia;Denmark;France;Germany;Hungary;India;Israel;Italy;Japan;Korea, Republic of;Netherlands;Norway;Poland;Portugal;Russian Federation;Serbia;Spain;Sweden;Switzerland;Taiwan;Thailand;Turkey;Ukraine;United Kingdom;United States;
Baxalta Innovations GmbH
2020 Phase 3 EUCTR2020-003348-10-GB Australia;Austria;Belgium;Brazil;Canada;China;Colombia;Czechia;Denmark;France;Germany;Hungary;India;Israel;Italy;Japan;Korea, Republic of;Netherlands;Norway;Poland;Portugal;Russian Federation;Serbia;Spain;Sweden;Switzerland;Taiwan;Thailand;Turkey;Ukraine;United Kingdom;United States;
- Phase 3 EUCTR2020-003348-10-PL Australia;Austria;Belgium;Brazil;Canada;China;Colombia;Czechia;Denmark;France;Germany;Hungary;India;Israel;Italy;Japan;Korea, Republic of;Netherlands;Norway;Poland;Portugal;Russian Federation;Serbia;Spain;Sweden;Switzerland;Taiwan;Thailand;Turkey;Ukraine;United Kingdom;United States;
- Phase 3 EUCTR2020-003348-10-AT Australia;Austria;Belgium;Brazil;Canada;China;Colombia;Czechia;Denmark;France;Germany;Hungary;India;Israel;Italy;Japan;Korea, Republic of;Netherlands;Norway;Poland;Portugal;Russian Federation;Serbia;Spain;Sweden;Switzerland;Taiwan;Thailand;Turkey;Ukraine;United Kingdom;United States;
Uniplas
Octapharma
2007 Phase 3 NCT00411801 United States;